A Comparison of Pediatric and Adult Safety Studies for Antipsychotic and Antidepressant Drugs Submitted to the United States Food and Drug Administration - 24/04/19
, Dionna J. Green, MD 4, Julie La, PharmD 5, Janelle M. Burnham, MD 3, Natella Rakhmanina, MD, PhD 1, Adelaide Robb, MD 1, Shiew Mei Huang, PhD 3, John N. van den Anker, MD, PhD 1Abstract |
Objective |
To examine the differences in the adverse drug reaction (ADR) profile of antipsychotic and antidepressant agents between pediatric and adult patients in studies submitted to the Food and Drug Administration (FDA) during the drug development process.
Study design |
Clinical trials in adult and pediatric patients were conducted by sponsors as part of the drug development programs for antipsychotic and antidepressant agents, and ADR information was collected as part of those trials and submitted to the FDA. Data collection was conducted by reviewing publicly available FDA-authored reviews and FDA-approved product labels for 10 drugs with an antipsychotic or an antidepressant indication from 2007 to 2017.
Results |
There were 308 drug and ADR combinations for the 10 drugs and drug combinations with 113 (36.7%) having a significantly different incidence in pediatric patients compared with adults. Sixty-eight (60.2%) of these ADRs had a significantly higher incidence in pediatric patients than in adults. Sedation was higher in 6 of the 10 drugs and drug combinations with risk differences ranging from 9.6 to 36.6%.
Conclusions |
This analysis indicates that there were significant differences between the pediatric and adult safety profiles of antipsychotic and antidepressant drugs. Sedation was the major ADR associated with the use of atypical antipsychotic drugs in pediatric patients. Clinicians caring for children should consider the ADR profile when prescribing antipsychotics and antidepressants in pediatric patients.
Le texte complet de cet article est disponible en PDF.Keywords : pediatric, drug development, regulatory, antipsychotic, antidepressant, adverse drug effects, US FDA
Abbreviations : ADR, FAERS, FDA, RD
Plan
| The opinions expressed in this article are those of the authors and should not be interpreted as the position of the US Food and Drug Administration. The authors declare no conflicts of interest. |
Vol 208
P. 236 - mai 2019 Retour au numéro
Article précédent
- Prenatal Maternal Psychological Distress and Offspring Risk for Recurrent Respiratory Infections
- Laura S. Korhonen, Linnea Karlsson, Noora M. Scheinin, Riikka Korja, Mimmi Tolvanen, Jussi Mertsola, Ville Peltola, Hasse Karlsson
- Acute Kidney Injury in Pediatric Cancer Patients
- Peong Gang Park, Che Ry Hong, Eunjeong Kang, Minsu Park, Hajeong Lee, Hyoung Jin Kang, Hee Young Shin, Il-Soo Ha, Hae Il Cheong, Hyung Jin Yoon, Hee Gyung Kang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?